Lysodel Therapeutics

Lysodel Therapeutics appears to have been a private biotechnology company focused on developing an innovative pharmaceutical product for obesity. Publicly available information on the company is extremely limited, and no robust company website, pipeline disclosure, financing history, or clinical development record could be confirmed from primary corporate sources. The clearest current reference found is a 2025 executive biography describing Lysodel Therapeutics as a company founded by Cuong Do and focused on obesity. Based on the lack of visible ongoing operations, clinical disclosures, or active corporate presence, the company appears inactive or dormant rather than an operating biotech with a public pipeline.